Evaluate Taditional Iranian product on mild to moderate alzheimer

Comparison of effectiveness of Davaie Loban and Placebo on severity of mild and moderate Alzheimer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014010216028N1

Enrollment

Registered

2014-03-19

Start date

2014-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MILD AND MODERATE ALZHEIMER. Dementia in Alzheimer's disease

Interventions

Intervention 1: Control group will be consumed placebo in the form of capsules containing starch of 500 mg per day, 3 capsules (1,500 mg) every 8 hours for 3 consecutive months., At the end of each m

Treatment - Drugs

Control group will be consumed placebo in the form of capsules containing starch of 500 mg per day, 3 capsules (1,500 mg) every 8 hours for 3 consecutive months., At the end of each month the assessm

Intervention group will be consumed davaie loban in the form of capsules of 500 mg per day, 3 capsules (1,500 mg) every 8 hours for 3 consecutive months.At the end of each month the assessment is don

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: At the beginning of the study,difinitive diagnose of mild to moderate Alzheimer’s disease according to 12= on Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog) and = 2 on Clinical Dementia Rating Scale (CDR); age between 50-80; the ability to participate in the study Exclusion criteria: Diseases such as hypertension;diabetes mellitus ; Patients with evidence of other neurodegenerative disorders; cardiovascular disease ; Clinically significant psychiatric diseases; Significant drug or alcohol misuse; Drugs with anticholinergic effects ; age over 80 years; not being able to participate in this study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of alzheimer. Timepoint: every 1 month for three month (0,1,2,3). Method of measurement: CDR (clinical dementia scaling)questionier.	—

Secondary

Measure	Time frame
Severity alzheimer. Timepoint: Every month for three month(0,1,2,3). Method of measurement: ADAS-COG( Alzheimer diesease Assesment scale cognitive behaivior)questionier.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHaleh tajadini

School of Traditional Medicine, Shahid Beheshti University of Medical Sciences

h.tajadini@sbmu.ac.irdr_haleh@yahoo.com+98 218877352125

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026